Silver Lining: Will GSK Case Increase Compliance In China?
This article was originally published in PharmAsia News
Executive Summary
Although it promises to be a bumpy road, the GSK investigation could lead to a more compliant health care industry with Chinese anti-bribery laws acting as a more forceful deterrent to local players than the U.S. Foreign Corrupt Practices Act.